(NASDAQ: HRMY) Harmony Biosciences Holdings's forecast annual revenue growth rate of 11.54% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.22%.
Harmony Biosciences Holdings's revenue in 2026 is $959,898,000.On average, 13 Wall Street analysts forecast HRMY's revenue for 2026 to be $61,439,394,615, with the lowest HRMY revenue forecast at $58,294,629,393, and the highest HRMY revenue forecast at $63,710,613,942. On average, 13 Wall Street analysts forecast HRMY's revenue for 2027 to be $69,126,598,491, with the lowest HRMY revenue forecast at $58,644,047,751, and the highest HRMY revenue forecast at $77,454,402,690.
In 2028, HRMY is forecast to generate $77,745,584,655 in revenue, with the lowest revenue forecast at $65,981,833,269 and the highest revenue forecast at $98,768,922,528.